PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15213258-0	2004	Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27.	Simvastatin	0-11	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	99-102	
15213258-3	2004	The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27.	Simvastatin	53-64	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	175-178	
15213258-3	2004	The current study explored the modulatory effects of simvastatin (SMV) on the angiotensin II (Ang II)-induced Rac1-mediated, upregulation of cyclin-dependent kinase inhibitor p27.	Simvastatin	66-69	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	175-178	
15213258-5	2004	Co-treatment of cells with SMV (1 microM) inhibited Ang II-induced upregulation of p27 protein.	Simvastatin	27-30	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	83-86	
15213258-6	2004	Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inhibitory effect of SMV on p27 protein expression, suggesting that the effect of SMV is geranylgeranyl dependent.	Simvastatin	113-116	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	120-123	
15213258-6	2004	Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inhibitory effect of SMV on p27 protein expression, suggesting that the effect of SMV is geranylgeranyl dependent.	Simvastatin	174-177	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	120-123	
15213258-8	2004	It was also shown that SMV, by inhibiting Rac1 activity, reversed Ang II-induced increase in intracellular H2O2 production, Akt activation, and p27 protein expression.	Simvastatin	23-26	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	144-147	
12379583-8	2002	In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1).	Simvastatin	32-35	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	157-160	
12379583-8	2002	In rats with pressure overload, SIM treatment significantly reduced Ras membrane targeting, Ras in vivo activation, ERK2 phosphorylation, and the ratio cdk4/p27(kip1).	Simvastatin	32-35	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	161-165	
12963647-7	2003	Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a.	Simvastatin	53-64	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	185-192	
10412745-6	1999	The aim of the present study is to examine the effect of simvastatin, one of the HMG-CoA reductase inhibitors, on the glomerular cell proliferation and on the expression of CDK2 or p27Kip1 in mesangial cells in experimental glomerulonephritis in vivo.	Simvastatin	57-68	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	181-188